Premium
Insight into the inhibitor discrimination by FLT 3 F691L
Author(s) -
Verma Sharad,
Singh Aditi,
Kumari Anchala,
Pandey Bharati,
Jamal Salma,
Goyal Sukriti,
Sinha Siddharth,
Grover Abhinav
Publication year - 2018
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.13169
Subject(s) - myeloid leukemia , cancer research , tyrosine kinase , protein kinase domain , tyrosine kinase inhibitor , chemistry , receptor tyrosine kinase , kinase , pharmacology , gene , biology , receptor , genetics , biochemistry , cancer , mutant
Fms‐like tyrosine kinase 3 ( FLT 3) belongs to the receptor tyrosine kinase family and expressed in hematopoietic progenitor cells. FLT 3 gene mutations are reported in ~30% of acute myeloid leukemia cases. FLT 3 kinase domain mutation F691L is one of the common causes of acquired resistance to the FLT 3 inhibitors including quizartinib. MZH 29 and crenolanib were previously reported to inhibit FLT 3 F691L. However, crenolanib was reported for the moderate inhibition. We found that Glu661and Asp829 were the most significant residues to target the FLT 3 F691L which contribute most significantly to the binding energy with MZH 29 and crenolanib. These interactions were found absent with quizartinib. Further free energy landscape analysis revealed that FLT 3 F691L bound to MZH 29 and crenolanib was more stable as compared to quizartinib.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom